2. Search Result
Search Result
Results for "

blood-brain barrier permeability，neurodegenerative diseases

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

1

Screening Libraries

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-161683
    Tyk2-IN-19

    		JAK Neurological Disease
    Tyk2-IN-19 (compound 1) is an orally active and blood-brain barrier (BBB) permeable Tyk2 inhibitor. Tyk2-IN-19 can be used for study of neurodegenerative diseases .
    Tyk2-IN-19
  • HY-14197
    Clorgyline
    4 Publications Verification

    M&B 9302

    		 Monoamine Oxidase Neurological Disease
    Clorgyline (M&B 9302) is an orally active, blood-brain barrier permeable and selective monoamine oxidase A (MAO-A) inhibitor. Clorgyline's selective inhibition of MAO-A leads to reduced metabolism of neurotransmitters such as serotonin (5-hydroxytryptamine), which accumulates in the brain. Clorgyline can be used in the study of depression and neurodegenerative diseases .
    Clorgyline
  • HY-160831
    PQQ-trimethylester

    PQQ-TME

    		 α-synuclein Neurological Disease
    PQQ-trimethylester (PQQ-TME) is a synthetic compound that is a trimethylester derivative of pyrroloquinoline quinone (PQQ). PQQ-trimethylester has twice the blood-brain barrier permeability of PQQ (HY-100196) in vitro. In addition, PQQ-trimethylester shows strong inhibitory activity against α-synuclein, amyloid β1-42 (Aβ1-42) and prion protein fibrillation. PQQ-trimethylester can be used in the study of neurodegenerative diseases .
    PQQ-trimethylester
  • HY-114869
    DPQ
    1 Publications Verification

    		 PARP Neurological Disease
    DPQ is a blood-brain barrier permeable and selective PARP-1 inhibitor that blocks PARP-1-mediated DNA damage repair and NAD +/ATP consumption, thereby inhibiting excessive inflammatory responses. DPQ inhibits NF-κB pathway activation, reduces the expression of pro-inflammatory factors (such as TNF-α, IL-6) and oxidative stress. DPQ can be used in inflammation-related studies of acute lung injury, myocardial infarction, and neurodegenerative diseases .
    DPQ
  • HY-161163
    IND 1316

    		AMPK Neurological Disease
    IND 1316 is an orally active, blood-brain barrier permeable AMPK activator with neuroprotective effects in animal models of Huntington's disease. IND 1316 can be used for research on neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease .
    IND 1316
  • HY-162693
    AChE-IN-68

    		Cholinesterase (ChE) Neurological Disease
    AChE-IN-68 (compound 2l) is a potent and selective AChE inhibitor, with an IC50 value of 0.040 μM. AChE-IN-68 has high blood-brain barrier permeability. AChE-IN-68 can be used for the research of neurodegenerative disorders, particularly Alzheimer’s disease .
    AChE-IN-68
  • HY-172460
    AChE/BChE/MAO-B-IN-5

    		Cholinesterase (ChE) Monoamine Oxidase Neurological Disease
    AChE/BChE/MAO-B-IN-5 is a multitarget inhibitor of cholinesterases (AChE and BChE) and monoamine oxidase MAO-B with blood–brain barrier permeability. It exhibits IC50 values of 0.24 µM, 6.29 µM, and 0.11 µM against AChE, BChE, and MAO-B, respectively. AChE/BChE/MAO-B-IN-5 shows promise for research in the field of neurodegenerative diseases such as Alzheimer's disease .
    AChE/BChE/MAO-B-IN-5
  • HY-W424851
    DPQ hydrochloride

    6,7-Dimethoxy-2-(1-piperazinyl)-4-quinazolinamine hydrochloride

    		 PARP Infection Inflammation/Immunology
    DPQ hydrochloride is a blood-brain barrier permeable and selective PARP-1 inhibitor that blocks PARP-1-mediated DNA damage repair and NAD +/ATP consumption, thereby inhibiting excessive inflammatory responses. DPQ hydrochloride inhibits NF-κB pathway activation, reduces the expression of pro-inflammatory factors (such as TNF-α, IL-6) and oxidative stress. DPQ hydrochloride can be used in inflammation-related studies of acute lung injury, myocardial infarction, and neurodegenerative diseases .
    DPQ hydrochloride
  • HY-W338446
    BF-170

    		Tau Protein Neurological Disease
    BF-170 is a selective tau fibril binding agent with an EC50 of 221 nM. It exhibits good blood-brain barrier permeability, and after intravenous injection in mice, the concentration in brain tissue reaches 9.1% ID/g within 2 minutes (with a brain clearance rate of 0.25% ID/g after 30 minutes). BF-170 can be used as a probe for tau protein pathology imaging in Alzheimer's disease (AD). It plays an important role in early-stage AD research and holds potential for imaging studies of tau-related neurodegenerative diseases .
    BF-170
  • HY-161461
    E234G HYPE-IN-1

    		Amylases Neurological Disease
    E234G HYPE-IN-1 (Compound I2.10) is an inhibitor of AMPylation directed by the Huntingtin-interacting protein E (HYPE), possessing low micromolar bioactivity, low cytotoxicity, and blood-brain barrier permeability. E234G HYPE-IN-1 can inhibit the AMPylation of B-cell immunoglobulin-binding protein (BiP), the primary substrate of HYPE. E234G HYPE-IN-1 is suitable for development as a HYPE-specific therapeutic agent for clinical conditions such as neurodegenerative diseases and diabetes .
    E234G HYPE-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: